{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:18:21Z","timestamp":1787980701120,"version":"build-2784847793"},"reference-count":10,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ccell.2026.02.009","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:53:08Z","timestamp":1772725988000},"page":"708-709","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tumor-restraining fibroblasts emerge after chemotherapy specifically in responders"],"prefix":"10.1016","volume":"44","author":[{"given":"Krishnan K.","family":"Mahadevan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghu","family":"Kalluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2026.02.009_bib1","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ccell.2026.01.012","article-title":"Lipid oxidation reprogramming in cancer-associated fibroblasts enhances CD8\u207a T cell cytotoxicity and therapeutic response","volume":"44","author":"Ma","year":"2026","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2026.02.009_bib2","article-title":"Insights into the relevance of targeting fibroblasts to control cancer","volume":"6","author":"Boeker","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ccell.2026.02.009_bib3","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1158\/2159-8290.CD-20-1484","article-title":"Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resistance in Pancreatic Cancer","volume":"12","author":"McAndrews","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.02.009_bib4","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","article-title":"Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival","volume":"25","author":"\u00d6zdemir","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2026.02.009_bib5","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.4161\/cbt.5.12.3354","article-title":"Identification of fibroblast heterogeneity in the tumor microenvironment","volume":"5","author":"Sugimoto","year":"2006","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ccell.2026.02.009_bib6","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.20.00590","article-title":"Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma","volume":"38","author":"Van Cutsem","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.02.009_bib7","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.4161\/cbt.6.11.4874","article-title":"Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer","volume":"6","author":"Narra","year":"2007","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ccell.2026.02.009_bib8","article-title":"Current Status of Research on Losartan in Tumour Therapy","volume":"30","author":"Wang","year":"2026","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ccell.2026.02.009_bib9","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2543614","article-title":"A phase 2 trial of CXCR4 antagonism and PD1 inhibition in metastatic pancreatic adenocarcinoma reveals recruitment of T cells but also immunosuppressive macrophages","volume":"14","author":"Bever","year":"2025","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ccell.2026.02.009_bib10","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae323","article-title":"Pembrolizumab +\/- paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction","volume":"30","author":"Chung","year":"2025","journal-title":"Oncologist"}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610826001078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610826001078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:26:26Z","timestamp":1787977586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610826001078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1535610826001078"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2026.02.009","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor-restraining fibroblasts emerge after chemotherapy specifically in responders","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2026.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2026.01.012","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}